Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies

Journal of Managed Care Pharmacy

Volumn 19, Issue SUPPL.1, 2013, Pages

  Owens, Gary M ^a   Olvey, Eleanor L ^b   Skrepnek, Grant H ^a,c   Pill, Michael W ^d  

^a Pulido Center for Health Outcomes and Pharmaco Economic Research ^*  (United States)

^b Department of Pharmacy Practice and Science   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Gemini Healthcare LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

ABSENTEEISM; ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRODUCTIVITY; RETROSPECTIVE STUDY;

EID: 84874828021     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.s1.s41     Document Type: Article

References (99)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606-16. Available at: http://brain.oxfordjournals. org/content/129/3/606.long. Accessed November 4, 2012.
2. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6(10):1-73.
3. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91-98.
4. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28(5):363-79.
5. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703-12. Available at: http://www.amcp.org/data/jmcp/703-712.pdf.
6. Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010;13(1):78-89.
7. Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351-62.
8. O'Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler. 2009;15(6):728-34.
9. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-49.
10. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-82.
11. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebocontrolled trial. Lancet. 2009;374(9700):1503-11.
12. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904. Available at: http://www.nejm.org/doi/full/10.1056/NEJM200009283431301. Accessed November 4, 2012.
13. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. Available at: http://www.nejm.org/doi/full/10.1056/ NEJMoa0909494. Accessed November 4, 2012.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
15. No author listed. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504.
16. No author listed. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61.
17. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-25.
18. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. Available at: http://www.nejm.org/doi/full/10.1056/ NEJMoa044397. Accessed November 4, 2012.
19. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
20. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402- Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0907839. Accessed November 4, 2012.
21. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
22. Tysabri (natalizumab) injection, for intravenous use. Biogen Idec Inc. January 20, 2012. Available at: http://www.tysabri.com/en_US/tysb-hcp/site/ pdfs/TYSABRI-pi.pdf. Accessed November 4, 2012.
23. Tysabri (natalizumab) 300 mg concentrate for solution for infusion. Biogen Idec Inc. June 2012. Available at: http://www.medicines.org.uk/emc/ medicine/18447/SPC/TYSABRI+300+mg+concentrate+for+solution+for+infus ion/#INDICATIONS. Accessed November 4, 2012.
24. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-52.
25. Novantrone (mitoxantrone) for injection concentrate. U.S. prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2010/019297s033s034lbl.pdf. Accessed November 4, 2012.
26. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90-98.
27. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52. Available at: http://amcp.org/data/jmcp/44-52.pdf.
28. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469-76. Available at: http://www.amcp.org/data/jmcp/ Research-469-476.pdf.
29. Dunn JD, Pill MW. A claims-based view of health care charges and utilization for commercially insured patients with osteoarthritis. Manag Care. 2009;18(12):44-50.
30. Garrett N, Martini EM. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag. 2007;10(2):51-60.
31. Forthman MT, Dove HG, Wooster LD. Episode Treatment Groups (ETGs): a patient classification system for measuring outcomes performance by episode of illness. Top Health Inf Manage. 2000;21(2):51-61.
32. Rosen AK, Mayer-Oakes A. Episodes of care: theoretical frameworks versus current operational realities. Jt Comm J Qual Improv. 1999;25(3):111-28.
33. Aforismo JF, Pill MW, Prescott JD. Initiating drug therapy in multiple sclerosis patients: effect on healthcare costs. Am J Pharm Benefits. 2010;2(1):59-65. Available at: http://www.ajpblive.com/media/pdf/ Aforismo_2-1.pdf. Accessed November 4, 2012.
34. Brandes DW, Shaya FT, Pill MW. Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis. Am J Manag Care. 2010;16(6 Suppl):S171-S177. Available at: http://www.ajmc.com/publications/ supplement/2010/A282_2010jun/A282_10jun_Brandes_S171toS177/. Accessed November 4, 2012.
35. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58(1):136-38.
36. Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis. 2010;7(1):A12. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811507/?tool=pubmed. Accessed November 4, 2012.
37. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-702.
38. Rajagopalan K, Brook RA, Beren IA, Kleinman NL. Comparing costs and absences for multiple sclerosis among US employees: pre- and posttreatment initiation. Curr Med Res Opin. 2011;27(1):179-88.
39. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70(13):1677-91.
40. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419-25.
41. Lad SP, Chapman CH, Vaninetti M, Steinman L, Green A, Boakye M. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology. 2010;35(2):93-99.
42. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ. 2010;13(3):464-71.
43. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;25(4):869-77.
44. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther. May 2009;26(5):552-62.
45. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61. Available at: http:// www.amcp.org/data/jmcp/245-61.pdf.
46. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25(6):1445-54.
47. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of diseasemodifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77(4):355-63.
48. Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009;7(2):91-108.
49. O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14(5):617-27.
50. Nuijten MJ, Dubois DJ. Cost-utility analysis: current methodological issues and future perspectives. Front Pharmacol. 2011;2:29. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/?tool=pubmed. Accessed November 4, 2012.
51. Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler. 2005;11(5):542-51.
52. Kobelt G, Jønsson L, Henriksson F, Fredrikson S, Jonsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care. 2000;16(3):768-80.
53. Kobelt G, Jønsson L, Miltenburger C, Jonsson B. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care. 2002;18(1):127-38.
54. Kobelt G, Jønsson L, Fredrikson S. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ. 2003;4(1):50-59.
55. Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14(5):679-90.
56. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326(7388):522. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC150460/?tool=pubmed. Accessed November 4, 2012.
57. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ. 1999;319(7224):1529-33. Available at: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC28295/?tool=pubmed. Accessed November 4, 2012.
58. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Costeffectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617-27.
59. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5(1):44-54.
60. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68(2):144-49. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1736797/pdf/ v068p00144.pdf. Accessed November 4, 2012.
61. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-68.
62. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003;25(2):611-34.
63. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657-65.
64. Lazzaro C, Bianchi C, Peracino L, Zacchetti P, Uccelli A. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci. 2009;30(1):21-31.
65. Phillips CJ, Gilmour L, Gale R, et al. A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4(1-4):35-50.
66. Bose U, Ladkani D, Burrell A, Sharief M. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4(1-4):207-19.
67. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC201004/?tool=pubmed. Accessed November 4, 2012.
68. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-55. Available at: http://www.amcp.org/data/ jmcp/543-555.pdf.
69. Becker III RV, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsingremitting multiple sclerosis. J Manag Care Pharm. 2011;17(5):377-81. Available at: http://www.amcp.org/JMCP/2011/June/9742/1033.html.
70. Bakhshai J, Bleu-Laine R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ. 2010;13(1):63-69.
71. Nuijten M, Mittendorf T. A health-economic evaluation of diseasemodifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther. 2010;32(4):717-28.
72. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care. 2000;16(3):751-67.
73. Lepen C, Coyle P, Vollmer T, Blumhardt L, Lilliu H, Beresniak A. Longterm cost effectiveness of interferon-beta-1a in the treatment of relapsingremitting multiple sclerosis: an econometric model. Clin Drug Investig. 2003;23(9):571-81.
74. Glad SB, Nyland H, Aarseth JH, Riise T, Myhr KM. How long can you keep working with benign multiple sclerosis? J Neurol Neurosurg Psych. 2011;82(1):78-82.
75. Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol. 2010;257(6):926-36.
76. Messmer Uccelli M, Specchia C, Battaglia MA, Miller DM. Factors that influence the employment status of people with multiple sclerosis: a multinational study. J Neurol. 2009;256(12):1989-96.
77. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. 2008;255(9):1354-60.
78. Roessler RT, Rumrill PD Jr, Hennessey ML, Vierstra C, Pugsley E, Pittman A. Perceived strengths and weaknesses in employment policies and services among people with multiple sclerosis: results of a national survey. Work. 2003;21(1):25-36.
79. Busche KD, Fisk JD, Murray TJ, Metz LM. Short term predictors of unemployment in multiple sclerosis patients. Can J Neurol Sci. 2003;30(2):137-42.
80. Campagnolo DI, Sun J, You X, Salter A, Laforet G, Fox R. Diseasemodifying therapy use and employment status of multiple sclerosis patients: data from the North American Research Committee on Multiple Sclerosis. Poster presented at: 15th Congress of the European Federation of Neurological Societies; September 10-13, 2011; Budapest, Hungary.
81. Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK. Absenteeism and health-benefit costs among employees with MS. Curr Med Res Opin. 2009;25(6):1469-76.
82. Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681-91.
83. Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work. 2006;27(2):143-51.
84. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsingremitting multiple sclerosis. Health Qual Life Outcomes. 2008;6:67. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542355/?tool=pubmed. Accessed November 4, 2012.
85. Lipsy RJ. Will the newer oral MS agents be welcomed by managed care organizations? Am J Manag Care. 2010;16(8 Suppl):S227-S233. Available at: http://www.ajmc.com/publications/supplement/2010/A309_10sep/ A309_10sep_Lipsy_S227to233/. Accessed November 4, 2012.
86. Szabo SM, Dembek C, Moore P, White LA, Wijaya H, Levy AR. Estimating net health benefits of intramuscular interferon beta-1a and fingolimod in treating patients with relapsing-remitting multiple sclerosis. Poster presented at: 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; November 5-8, 2011; Madrid, Spain.
87. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299-308.
88. Lublin F, Cofield S, Cutter G, et al. The CombiRx Trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing-remitting multiple sclerosis-clinical outcomes. Neurology. 2012;78(Meeting Abstracts 1):PL02.003. Available at: http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/PL02.003. Accessed November 4, 2012.
89. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001;56(10):1324-30.
90. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-50.
91. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006;63(12):1686-91.
92. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol. 2006;253(3):287-93.
93. Lukas C, Minneboo A, de Groot V, et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psych. 2010;81(12):1351-56.
94. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009;282(1-2):106-11. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2726444/?tool=pubmed. Accessed November 4, 2012.
95. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadoliniumenhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353(9157):964-99.
96. Rovaris M, Agosta F, Sormani MP, et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain. 2003;126(Pt 10):2323-32. Available at: http://brain. oxfordjournals.org/content/126/10/2323.long. Accessed November 4, 2012.
97. Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. J Neurol. 2008;255(9):1378-83.
98. Zivadinov R, Stosic M, Cox JL, Ramasamy DP, Dwyer MG. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol. 2008;255(Suppl 1):61-74.
99. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci. 2011;305(1-2):1-10.